MK-677, also called ibutamoren, sits in an unapproved and largely unregulated middle ground that is routinely misread as either fully legal or outright banned. The honest bottom line is narrower: it is an orally active, non-peptide ghrelin-mimetic growth hormone secretagogue that has been studied in clinical trials but has never received FDA approval for any indication, so it cannot be lawfully marketed as a drug or dietary supplement for human use, and it is sold instead through the research chemical channel under research-use-only labeling. That status carries direct consequences for cost, legal exposure, and eligibility in tested sport, which is why the bottom line is best stated plainly before the detail.
MK-677 is not FDA-approved for any indication, is not a federally scheduled controlled substance, is sold only as a research chemical, and is banned in sport by the World Anti-Doping Agency at all times.
The record shows no approval at any point: ibutamoren has never cleared the FDA for any medical indication, and no approved prescription product containing it exists in the United States. It reached late-stage clinical investigation as a candidate for stimulating growth hormone and insulin-like growth factor 1 in conditions such as age-related muscle wasting, frailty, hip fracture recovery, and growth hormone deficiency, but the sponsor discontinued development after trials failed to show a favorable balance of meaningful functional benefit against side effects that included elevated blood glucose and fluid retention. For a reader weighing legal exposure, that unapproved status closes off both the off-label and the supplement routes that approved products enjoy.
MK-677 has never received FDA approval for any indication, and because it was first studied as an investigational new drug it is barred from the dietary supplement category under the Dietary Supplement Health and Education Act.
The published descriptions of the United States market are consistent: MK-677 moves almost entirely through the research chemical channel, a category that exists in the gap between approved pharmaceuticals and dietary supplements. Vendors present it as a reference compound for laboratory research, attach not-for-human-consumption disclaimers, and often require buyers to acknowledge those terms at checkout, a framing that lets sellers move a compound with no lawful path to market while distancing themselves from the human use that drives demand. The financial and legal weight of that channel choice falls on the purchaser, who buys outside any pharmacy or supplement safeguard.
MK-677 is sold in the United States only through the research chemical channel under research-use-only disclaimers, because it qualifies for neither the FDA-approved prescription pharmacy channel nor the DSHEA-eligible supplement channel.
The most common misconception here is that an unscheduled status means a clean legal slate, and the record does not support that reading. MK-677 appears on no schedule of the federal Controlled Substances Act, so it is not a controlled substance the way anabolic-androgenic steroids, which Congress placed in Schedule III, are. The distinction turns on chemistry: the anabolic steroid statutes target compounds related to testosterone, while ibutamoren is a non-steroidal ghrelin receptor agonist that prompts the body's own growth hormone release, so it falls outside the definitions that trigger scheduling.
MK-677 is not listed on any schedule of the federal Controlled Substances Act, so mere possession is not a federal drug crime, but that unscheduled status does not address the separate FDA prohibitions on selling it for human use or any stricter state-level restrictions.
The not-for-human-consumption label reads as a quality marker but functions as a liability and compliance device. By declaring a compound sold strictly for laboratory research, a vendor tries to pull the product out of the regulatory categories that govern drugs and supplements and shift responsibility for any ingestion onto the purchaser. The practical meaning for anyone using the substance is a market with no identity, purity, dosage, or sterility assurances behind it.
The not-for-human-consumption label is a liability and compliance device that shifts ingestion responsibility to the purchaser and carries no assurance of identity, purity, dosage accuracy, or sterility, because research chemicals are not made under pharmaceutical or supplement good manufacturing practice standards.
For athletes the picture is unambiguous in a way the rest of the regulatory record is not. The World Anti-Doping Agency lists MK-677 as a prohibited substance under the peptide hormones, growth factors, related substances, and mimetics category, within the grouping that captures growth hormone secretagogues and ghrelin receptor agonists. The prohibition runs at all times, in and out of competition, so the career stakes for a tested athlete do not pause during the off-season.
| Dimension | WADA treatment of MK-677 |
|---|---|
| List category | Peptide hormones, growth factors, related substances, and mimetics |
| Prohibition window | At all times, in and out of competition |
| Detection | Accredited labs screen for ibutamoren and its metabolites in urine |
| Sanction | Typically multi-year ineligibility, results disqualified, reputational damage |
| Reach | Olympic and signatory federations plus many pro leagues, collegiate associations, and tactical organizations |
The World Anti-Doping Agency prohibits MK-677 at all times, both in and out of competition, as a growth hormone secretagogue under the peptide hormones, growth factors, related substances, and mimetics category, and a confirmed finding typically carries a multi-year period of ineligibility.
The cautionary reality is that an unscheduled compound is not a risk-free one, and the exposure is not the same for both sides of the transaction. A seller who markets MK-677 with claims about muscle growth, recovery, or anti-aging, or who otherwise signals intended human use, can trigger FDA enforcement for selling an unapproved new drug and for misbranding, a path that commonly opens with a warning letter and can escalate to product seizures, injunctions, and, in egregious cases, criminal referral. The pivotal factor across every scenario is intent: once a transaction is framed around human consumption, the analysis shifts from an unscheduled research compound to an unapproved drug.
Selling MK-677 with human-use claims can trigger FDA enforcement for an unapproved new drug and misbranding, ranging from warning letters to seizures, injunctions, and in egregious cases criminal referral, with the legal analysis turning on whether the transaction is framed around human consumption.
Outside the United States the treatment is uneven, and the absence of a single global framework means a compound that is unapproved in one country can be tightly restricted in another. The practical consequence is that a quantity which clears customs in one jurisdiction may be seized in another, and where the compound is classified as a restricted or prescription-only medicine, unauthorized supply can move from an administrative matter to a prosecutable offense.
| Jurisdiction | Regulatory treatment |
|---|---|
| EU and UK | Treated as an unauthorized medicinal product; sale for human use prohibited, with regulatory penalties for supply |
| Australia | Among the strictest; growth hormone secretagogues handled as prescription-only or controlled under the poisons standard, import requiring authorization |
| Canada | Regarded as an unapproved drug without market authorization, restricting lawful sale |
Outside the United States MK-677 is widely treated as an unapproved or unauthorized medicinal product, with the European Union, United Kingdom, and Canada barring its sale for human use and Australia handling growth hormone secretagogues as prescription-only or controlled under its poisons standard.
In the development pipeline MK-677 is best described as a stalled investigational compound, not an active late-stage candidate. It was carried through multiple clinical trials by sponsors holding the investigational rights, reaching studies that tested it for conditions tied to growth hormone and insulin-like growth factor 1, but formal development was discontinued when the results did not justify pursuing approval, and it has since lingered without an active sponsor. That abandoned status carries a direct legal consequence that explains where the compound is sold today.
MK-677 is a stalled investigational compound whose late-stage development was discontinued, and because it was first studied as an investigational new drug it is barred from the dietary supplement category, leaving the research chemical channel as the only place it persists.
Educational use only. This article describes what the published scientific and clinical literature reports about MK-677. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
